Article
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Leukemia - 1 Jan 2022
Yang Jing, Weisberg Ellen L, Liu Xiaoxi, Magin Robert S, Chan Wai Cheung, Hu Bin, Schauer Nathan J, Zhang Shengzhe, Lamberto Ilaria, Doherty Laura, Meng Chengcheng, Sattler Martin, Cabal-Hierro Lucia, Winer Eric, Stone Richard, Marto Jarrod A, Griffin James D, Buhrlage Sara J
Abstract excerpt
Mutations in the Janus Kinase 2 (JAK2) gene resulting in constitutive kinase activation represent the most common genetic event in myeloproliferative neoplasms (MPN), a group of diseases involving overproduction of one or more kinds of blood cells, including red cells, white cells, and platelets. JAK2 kinase inhibitors, such as ruxolitinib, provide clinical benefit, but inhibition of wild-type (wt) JAK2 limits...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.